- Home
- JANX vs DC Comparison
JANX vs DC Comparison
Compare JANX & DC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | DC |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 975.7M | 783.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | JANX | DC |
|---|---|---|
| Price | $18.05 | $6.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $47.00 | $9.48 |
| AVG Volume (30 Days) | 670.8K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $3.79 |
| 52 Week High | $35.34 | $7.25 |
Technical Indicators
Market Signals| Indicator | JANX | DC |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 60.60 |
| Support Level | $13.13 | $5.79 |
| Resistance Level | $35.34 | $6.57 |
| Average True Range (ATR) | 0.64 | 0.26 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 82.07 | 53.44 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company focused on revitalizing the Homestake District in Lead, South Dakota. The company holds gold mineral properties surrounding the historic Homestake Mine and is advancing key projects, including the Richmond Hill Project.